Neonatal supraventricular tachycardia (SVT)
Narrow-complex tachycardia in the newborn · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Neonatal SVT is a regular narrow-complex tachycardia, usually from an accessory pathway (AV re-entrant tachycardia), typically with rates around 220–300/min and little beat-to-beat variability. Prolonged SVT can cause heart failure and cardiovascular collapse and requires prompt termination.
Red flags
- Signs of shock or heart failure
- Reduced conscious level or poor perfusion
- Very prolonged SVT (risk of tachycardia-induced cardiomyopathy)
- Broad-complex tachycardia (treat as VT until proven otherwise)
- Recurrent SVT despite treatment
Assessment
Differential diagnosis
- Sinus tachycardia (secondary to sepsis, pain, fever, hypovolaemia)
- Atrial flutter
- Ventricular tachycardia (broad complex)
- SVT with aberrancy
- Congenital heart disease with arrhythmia
- Metabolic/electrolyte disturbance or drug effect
Investigations
- 12-lead ECG (and rhythm strip) to confirm rate, QRS width and P-wave relationship
- Continuous cardiac monitoring and SpO2
- Echocardiography to assess structure and ventricular function
- Electrolytes, calcium, magnesium, glucose
- Blood gas and lactate (assess perfusion)
- Sepsis screen if sinus tachycardia possible
Management
- Confirm the rhythm: narrow-complex, very fast, regular, minimal rate variability (distinguish from sinus tachycardia which varies and is usually <220/min).
- Assess haemodynamic stability (perfusion, BP, conscious level, signs of heart failure).
- Attach continuous monitoring, obtain IV/IO access and a 12-lead ECG, and record the rhythm during any intervention.
- In a STABLE infant, attempt vagal manoeuvres first: apply a bag of iced water/ice to the face (diving reflex) for a few seconds.
- If vagal manoeuvres fail in a stable infant with reliable IV access, give rapid-push adenosine via a large proximal vein with immediate saline flush, escalating the dose if needed.
- Record a continuous ECG during adenosine to capture the mechanism of termination.
- In an UNSTABLE infant (shock/collapse), perform urgent synchronised DC cardioversion.
- Correct contributing factors: electrolytes, acidosis, temperature and treat heart failure.
- After conversion, obtain a 12-lead ECG looking for pre-excitation (delta wave/WPW).
- Involve paediatric cardiology for maintenance therapy and to plan longer-term management.
- Start maintenance anti-arrhythmic therapy to prevent recurrence as advised by cardiology.
- Educate parents on recurrence and when to seek help; arrange cardiology follow-up.
Drugs & doses
Adenosine 0.1 mg/kg (100 microgram/kg) rapid IV/IO bolus with immediate flush; increase to 0.2 then up to 0.3 mg/kg if needed
Synchronised DC cardioversion 1 J/kg, increasing to 2 J/kg for the unstable infant
Flecainide or propranolol (e.g. propranolol 0.25–1 mg/kg/dose PO 6–8-hourly) for maintenance, under cardiology guidance
Amiodarone 5 mg/kg IV over 20–60 min (specialist use) for refractory tachyarrhythmia
Avoid verapamil in infants (risk of profound hypotension and arrest)
Disposition
NICU/PICU-level monitoring with cardiology involvement; stabilise, start maintenance therapy and arrange cardiology follow-up and family education.
Complications & pitfalls
- Cardiogenic shock and collapse
- Tachycardia-induced cardiomyopathy and heart failure
- Recurrence requiring long-term therapy
- Adverse effects of anti-arrhythmics (bradycardia, hypotension)
- Rarely, association with structural heart disease
Exam pearls
- Sinus tachycardia varies with activity and is usually <220/min; SVT is fast, fixed and monotonous.
- Adenosine must be given as a rapid push into a large vein with an immediate flush to work.
- Record a continuous ECG during adenosine – it is diagnostic as well as therapeutic.
- Avoid verapamil in neonates and young infants.
- An unstable infant needs synchronised cardioversion, not repeated drug attempts.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.